Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A

Next Previous
Trial Profile

Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Turoctocog alfa pegol (Primary)
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Acronyms PATHFINDER 3
  • Sponsors Novo Nordisk; Novo Nordisk Pharma

Most Recent Events

  • 01 Jan 2022 Post hoc analysis was performed by applying datamining techniques retrospectively to the final results of the pathfinder 2 and 3 clinical trials and analysing the resulting data descriptively; results published in the Haemophilia
  • 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology
  • 20 Jun 2019 According to a Novo Nordisk media release, the European Commission has granted marketing authorisation for Esperoct for the treatment of adolescents (=12 years of age) and adults with haemophilia A.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top